Biofrontera defers ~$4.3-4.5M payment to Feb 29; warrants exercised for 888K shares

Biofrontera Inc.

Payment due Jan 31, 2024 deferred to Feb 29, 2024 under amended addendum to license and supply agreement.
Institutional investor exercised pre-funded warrants for 888,000 shares; all such warrants now exercised.
Total outstanding shares post-exercise: 2,572,628.
Amended addendum details payment schedule: $2.791M due Dec 20, 2023; remainder and ~$2.9M PO due Feb 29.
Failure to make timely payments under schedule constitutes immediate material breach with no cure period.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Biofrontera Inc. amended LSA with Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, Biofrontera AG (effective 2024-01-26).

Action: amendment
Agreement: supply
Counterparty: Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, Biofrontera AG
Effective: 2024-01-26

Exact text from the filing

On January 29, 2024, Biofrontera Inc. (the “ Company ”) entered into an amendment and restatement (the “ Amendment ”), effective January 26, 2024, of an Addendum (the “ Addendum ”), entered into on December 12, 2023, to its Amended and Restated License and Supply Agreement, dated as of June 16, 2021 (as previously amended, the “LSA”), by and among the Company, Biofrontera Pharma GmbH (“Pharma”), and Biofrontera Bioscience GmbH (“Bioscience”).

View on SEC.gov

Browse all material agreements →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-004771

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.